DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Caligan - 1 David Johnson - 1 Ohtuvayre - 1 Verona's - 1 Verona - 1 MorphoSys - 1 bode - 1 Ken Squire - 1
Top related locs:
Verona London MorphoSys Caligan's
Top related orgs:
Verona Pharma - 1 Caligan Partners - 1 Carlyle Group - 1 FDA - 1 MorphoSys AG - 1 Novartis - 1 pharma - 1 13D - 1

Search resuls for: "Caligan's"


2 mentions found


☆ Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value
  + stars: | 2024-11-09 | by ( Kenneth Squire | ) www.cnbc.com   time to read: +7 min
It invests in a concentrated portfolio of small and midcap life sciences companies, using activism as a tool to unlock value. A successful drug like Ohtuvayre would not just increase the life expectancies of patients with COPD, but it would lower costs for both health-care providers and COPD patients. Currently, there are over 8.6 million U.S. COPD patients with over 4 million remaining symptomatic despite treatment from the current commercial therapies. In early pooling analysis, Ohtuvayre showed a 41% reduction in exacerbations in COPD patients, almost double brensocatib. When Caligan announced its Verona position last month, the stock was trading at $33.40 per share or a $2.5 billion enterprise value.
Persons: Caligan, David Johnson, Ohtuvayre, Verona's, Verona, MorphoSys, bode, Ken Squire Organizations: Verona Pharma, Caligan Partners, Carlyle Group, FDA, MorphoSys AG, Novartis, pharma, 13D Locations: Verona, London, MorphoSys, Caligan's
☆ Exclusive: Caligan urges Anika Therapeutics to conduct review, plans board challenge
  + stars: | 2023-02-21 | by ( Svea Herbst-Bayliss | ) www.reuters.com   time to read: +3 min
Caligan Partners owns a roughly 4% stake in Anika and is ratcheting up pressure to protest an underperforming stock price and losses at the company's joint preservation segment. "Anika may be better positioned as a private company or as part of a larger organization," Caligan's managing partner, David Johnson, wrote to the board. Anika's osteoarthritis knee pain relief injection treatments would be attractive to other companies and could be worth almost $60 per share, Johnson wrote. On Tuesday, the company's stock price climbed nearly 6% as the broader market declined. Anika is best known for its viscosupplement portfolio, including Monovisc and Orthovisc, marketed by Johnson & Johnson (JNJ.N).
0 next >>
Total: 2